ArticleBMC infectious diseases2026
Factors associated with HCV coinfection and preferences for HCV screening services among people living with HIV/AIDS.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe high prevalence of HCV coinfection among people living with HIV/AIDS has become a serious public health issue. This study aimed to understand the prevalence of HCV coinfection and its associated factors among people living with HIV/AIDS who were under follow-up care, as well as to explore their preferences for HCV screening methods.
methodsThe study selected people living with HIV/AIDS who were receiving follow-up treatment in a district of Southwest China, up to September 30, 2025. Demographic information and details about the HIV infection route were collected from the HIV/AIDS follow-up management database. Blood samples were collected from these patients to test for anti-HCV and HCV core antigens. For those with positive HCV antibodies but negative core antigens, HCV RNA was quantitatively detected using high-precision methods. Multivariable logistic regression was used to analyze the factors influencing HCV coinfection among people living with HIV/AIDS. A discrete choice experiment was conducted to investigate the preferences of 219 people living with HIV/AIDS regarding four free HCV screening attributes: testing institutions, transportation subsidies, result collection time, and screening interval.
resultsA total of 1,014 people living with HIV/AIDS who were screened for anti-HCV and HCV core antigens were included in this study. Among them, 27 (2.66%) tested positive for HCV RNA or HCV core antigen. Multivariable logistic regression analysis revealed that the risk of HCV coinfection was 4.79 times higher in divorced or widowed individuals compared to married individuals with a spouse (95%CI: 1.76-13.01, P = 0.002). HIV/AIDS patients with a history of injecting drug use had a 41.70 times higher risk of HCV coinfection compared to those infected through heterosexual transmission (95%CI: 6.72-258.68, P < 0.001). The testing institution, transportation subsidies, and result collection time were key factors influencing participation in free HCV screening among people living with HIV/AIDS (all P < 0.05). Participants preferred HCV screening methods conducted at ART medication distribution sites (β = 1.685), with transportation subsidies of 50 yuan or less (β = 0.707), and same-day result collection (β = 0.269). The relative importance analysis of the attributes showed that the testing institution was the most important factor in choosing an HCV screening method (62.55%), followed by transportation subsidies (26.24%).
conclusionThe prevalence of HCV coinfection among people living with HIV/AIDS in a district of Southwest China is at a moderate to low level. Divorced or widowed individuals and those who inject drugs should be prioritized for HCV screening. Integrating HCV screening into ART medication dispensing sites, providing transportation subsidies, and improving the timeliness of result feedback may help increase the acceptance and accessibility of HCV screening among people living with HIV/AIDS. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.